By Henric Sundlof • 04 March 2020 • 15:55
The European Union has now approved a new medicine to treat depression in the form of a nose spray. So far, more than 100 Europeans have tested the spray in clinical treatment studies, with promising results.
But this new medicine is not without its controversy. The spray has been criticised in several countries around the world. The reason for this is that the nose spray contains the substance esketamine, which is classified as a drug. It’s actually an even stronger version of the known party drug ketamine.
European doctors think that as many as 90,000 to 300,000 people per year could be approved for treatment with this new medicine in Europe.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our
Download our media pack in either English or Spanish.